Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux.
暂无分享,去创建一个
Ian A. Watson | Prashant V Desai | Ian A Watson | Thomas J. Raub | G. Sawada | Thomas J Raub | P. Desai | Geri A Sawada
[1] T. Tsuruo,et al. Purification of the 170- to 180-kilodalton membrane glycoprotein associated with multidrug resistance. 170- to 180-kilodalton membrane glycoprotein is an ATPase. , 1988, The Journal of biological chemistry.
[2] W. Loh,et al. SPLIT SELECTION METHODS FOR CLASSIFICATION TREES , 1997 .
[3] P. Selzer,et al. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.
[4] Steven L. Dixon,et al. Use of Robust Classification Techniques for the Prediction of Human Cytochrome P450 2D6 Inhibition. , 2003 .
[5] Michal Vieth,et al. Structure-guided expansion of kinase fragment libraries driven by support vector machine models. , 2010, Biochimica et biophysica acta.
[6] Remigijus Didziapetris,et al. Fragmental Methods in the Design of New Compounds. Applications of The Advanced Algorithm Builder , 2002 .
[7] A. Tropsha,et al. Beware of q2! , 2002, Journal of molecular graphics & modelling.
[8] Yue Weng,et al. Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding , 2009, Science.
[9] A. Seelig. A general pattern for substrate recognition by P-glycoprotein. , 1998, European journal of biochemistry.
[10] Leo Breiman,et al. Bagging Predictors , 1996, Machine Learning.
[11] B. Kuhn,et al. Intramolecular hydrogen bonding in medicinal chemistry. , 2010, Journal of medicinal chemistry.
[12] P. Borst,et al. What have we learnt thus far from mice with disrupted P-glycoprotein genes? , 1996, European journal of cancer.
[13] Yiyu Cheng,et al. Identifying P-Glycoprotein Substrates Using a Support Vector Machine Optimized by a Particle Swarm , 2007, J. Chem. Inf. Model..
[14] Ronald T. Borchardt,et al. Quantitative Approaches to Delineate Passive Transport Mechanisms in Cell Culture Monolayers , 1999 .
[15] Bin Chen,et al. Comparison of Random Forest and Pipeline Pilot Naïve Bayes in Prospective QSAR Predictions , 2012, J. Chem. Inf. Model..
[16] Jeffrey W Cramer,et al. Strategies for conducting ADME studies during lead generation in the drug discovery process. , 2010, IDrugs : the investigational drugs journal.
[17] J. Greenwood. Characterization of a rat retinal endothelial cell culture and the expression of P-glycoprotein in brain and retinal endothelium in vitro , 1992, Journal of Neuroimmunology.
[18] Thomas J. Raub,et al. In vitro models of the blood-brain barrier. , 1998, Alternatives to laboratory animals : ATLA.
[19] J. Riordan,et al. The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. , 1986, Biochemical and biophysical research communications.
[20] Gabriele Cruciani,et al. A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR. , 2005, Journal of medicinal chemistry.
[21] Wei Zhou,et al. High-Dimensional Descriptor Selection and Computational QSAR Modeling for Antitumor Activity of ARC-111 Analogues Based on Support Vector Regression (SVR) , 2012, International journal of molecular sciences.
[22] Ovidiu Ivanciuc,et al. Applications of Support Vector Machines in Chemistry , 2007 .
[23] Jörg Huwyler,et al. Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. , 2003, Journal of medicinal chemistry.
[24] Robert P. Sheridan,et al. Random Forest: A Classification and Regression Tool for Compound Classification and QSAR Modeling , 2003, J. Chem. Inf. Comput. Sci..
[25] Lei Chen,et al. ADME evaluation in drug discovery. 10. Predictions of P-glycoprotein inhibitors using recursive partitioning and naive Bayesian classification techniques. , 2011, Molecular pharmaceutics.
[26] Jing Lu,et al. Development of in silico models for human liver microsomal stability , 2007, J. Comput. Aided Mol. Des..
[27] A. Seelig,et al. P-glycoprotein senses its substrates and the lateral membrane packing density: consequences for the catalytic cycle. , 2008, Biochemistry.
[28] J. Polli,et al. Rational use of in vitro P-glycoprotein assays in drug discovery. , 2001, The Journal of pharmacology and experimental therapeutics.
[29] Alexander Golbraikh,et al. Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection , 2002, J. Comput. Aided Mol. Des..
[30] A. Dantzig,et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. , 1996, Cancer research.
[31] M. Melamed,et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[32] Carol L. Williams,et al. Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia. , 1989, The Journal of biological chemistry.
[33] D. Manallack,et al. Theoretical hydrogen bonding parameters for drug design. , 2001, Journal of molecular graphics & modelling.
[34] H. Kubinyi,et al. Three-dimensional quantitative similarity-activity relationships (3D QSiAR) from SEAL similarity matrices. , 1998, Journal of medicinal chemistry.
[35] R L Juliano,et al. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.
[36] A. Seelig,et al. Exploring the P-glycoprotein binding cavity with polyoxyethylene alkyl ethers. , 2010, Biophysical journal.
[37] T. Tsuruo,et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. , 1988, Cancer research.
[38] M. Yamazaki,et al. Clinical Relevance of P-Glycoprotein in Drug Therapy , 2003, Drug metabolism reviews.
[39] Michael H. Abraham,et al. Scales of solute hydrogen-bonding: their construction and application to physicochemical and biochemical processes , 2010 .
[40] I. Pastan,et al. ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[41] Remigijus Didziapetris,et al. Classification Analysis of P-Glycoprotein Substrate Specificity , 2003, Journal of drug targeting.
[42] Ying Xue,et al. Prediction of P‐Glycoprotein Substrates by a Support Vector Machine Approach. , 2004 .
[43] Thomas J. Raub,et al. P-glycoprotein recognition of substrates and circumvention through rational drug design. , 2006, Molecular pharmaceutics.
[44] S. Hitchcock,et al. Structural modifications that alter the P-glycoprotein efflux properties of compounds. , 2012, Journal of medicinal chemistry.
[45] J. Hochman,et al. Evaluation of drug interactions with P-glycoprotein in drug discovery: in vitro assessment of the potential for drug-drug interactions with P-glycoprotein. , 2002, Current drug metabolism.
[46] Paola Gramatica,et al. Principles of QSAR models validation: internal and external , 2007 .
[47] Vijay K Gombar,et al. Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model. , 2004, Journal of pharmaceutical sciences.
[48] Lei Chen,et al. Computational models for predicting substrates or inhibitors of P-glycoprotein. , 2012, Drug discovery today.
[49] M. Gleeson. Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.
[50] Geri A. Sawada,et al. Early Preclinical Evaluation of Brain Exposure in Support of Hit Identification and Lead Optimization , 2006 .
[51] D. Mudra,et al. In silico, in vitro and in situ models to assess interplay between CYP3A and P-gp. , 2011, Current drug metabolism.
[52] Li Di,et al. Development of QSAR models for microsomal stability: identification of good and bad structural features for rat, human and mouse microsomal stability , 2010, J. Comput. Aided Mol. Des..
[53] M C Willingham,et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[54] Alexander Golbraikh,et al. Combinatorial QSAR Modeling of P-Glycoprotein Substrates , 2006, J. Chem. Inf. Model..
[55] Robert P. Sheridan,et al. Similarity to Molecules in the Training Set Is a Good Discriminator for Prediction Accuracy in QSAR , 2004, J. Chem. Inf. Model..
[56] Thomas J. Raub,et al. How hydrogen bonds impact P-glycoprotein transport and permeability. , 2012, Bioorganic & medicinal chemistry letters.
[57] I. Wilhelm,et al. In vitro models of the blood-brain barrier. , 2011, Acta neurobiologiae experimentalis.
[58] I. Pastan,et al. Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. , 1986, Science.